Comparative Pharmacology
Head-to-head clinical analysis: ESKALITH CR versus LITHOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESKALITH CR versus LITHOBID.
ESKALITH CR vs LITHOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmitter activity, inhibits inositol monophosphatase, affects G-protein signaling, and alters gene expression for neuroprotective effects.
Lithium modulates neurotransmitter receptors and second messenger systems; inhibits inositol monophosphatase, reducing phosphoinositide signaling; alters ion transport; enhances serotonin and norepinephrine reuptake; modulates G-proteins.
Lithium carbonate extended-release (Eskalith CR) is administered orally. Typical adult starting dose: 300 mg 2-3 times daily. Maintenance dose: 900-1200 mg/day in 2-3 divided doses. Dose adjustments guided by serum lithium levels (target 0.6-1.2 mEq/L). Maximum dose: 2400 mg/day.
300-600 mg orally 2-3 times daily; extended-release formulation (LITHOBID) 300-450 mg orally twice daily.
None Documented
None Documented
Terminal half-life: 18–24 hours (single dose); 24–36 hours (steady state). Extended due to slow tissue redistribution and age-related decreased GFR.
Terminal elimination half-life: 18-36 hours (mean 24 hours) in young adults, increases with age and renal impairment. Long half-life supports once-daily dosing in sustained-release formulation.
Renal: >95% unchanged. Biliary/fecal: negligible (<1%).
Renal: >95% excreted unchanged in urine. Biliary/fecal: <5%.
Category C
Category C
Mood Stabilizer
Mood Stabilizer